Biological pipelines for oncology indications are evolving, with next-generation molecules joining more traditional monoclonal antibodies. These advances increase pressure on cell line construction timelines and create challenges in identifying cell lines that meet production needs. Through decades of expertise, Lonza continue to optimize the industry-leading GS Gene Expression System® to address these demands. Using a customer case study, we present on how GS piggyBac® transposon technology can boost titers and increase the chances of selecting a high performing clonal cell line. We also present the latest addition to our GS® toolbox, the GS Effex® cell line, for the production of cancer antibody therapeutics with increased potency.
Latest content
Latest briefing from the Knowledge Center